PBF 1650

Drug Profile

PBF 1650

Alternative Names: PBF-1650

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palobiofarma
  • Class Antipsoriatics; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis; Psoriasis
  • Discontinued Idiopathic thrombocytopenic purpura

Most Recent Events

  • 14 Jun 2018 Discontinued - Preclinical for Idiopathic thrombocytopenic purpura in Spain (PO)
  • 14 Jun 2018 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) (PO) (Palobiofarma pipeline, June 2018)
  • 14 Jun 2018 Phase-I clinical trials in Psoriasis (In volunteers) (PO) (Palobiofarma pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top